|
시장보고서
상품코드
1562250
아시아태평양의 감염성 질환 치료제 시장 전망(-2030년) : 지역별 분석 - 약효군별, 적응증별, 투여 경로별, 유통 채널별Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel |
||||||
아시아태평양의 감염병 치료제 시장은 2022년 259억 461만 달러로 평가되었고, 2030년에는 374억 1,507만 달러에 달할 것으로 예상되며, 2022-2030년간 4.7%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 추정됩니다.
신흥국 시장에서의 기회 확대로 아시아태평양 감염병 치료제 시장 성장 전망
감염병 발병률 증가로 인해 신흥국의 감염병 치료제 매출이 증가할 것으로 예상됩니다. 아시아태평양은 데이터 요구사항이 완만하고 규제가 덜 까다롭기 때문에 적응이 용이하고 비즈니스에 적합한 지역입니다. 또한, 신흥국의 보건 연구 및 생명과학에 대한 높은 투자는 개발도상국에서 최신 기술을 촉진하는 데 중요한 역할을 하고 있으며, 이는 감염성 질환 진단 및 치료에 대한 관심을 뒷받침하고 있습니다. 예를 들어, 유엔에이즈기구(UNAIDS)는 에이즈 퇴치를 위한 중저소득 국가들의 요구를 충족시키기 위해 2025년까지 290억 달러의 투자를 요구하고 있습니다. 따라서 인도와 한국의 신흥 감염병 치료제 시장에서 중요한 감염병 치료제 제조업체들은 향후 유리한 사업 기회를 맞이할 것으로 예상됩니다. 그 배경에는 간염, HAI, HIV, 독감 등 감염성 질환의 확산, 환자 수 증가, 국민들의 가처분 소득 증가, 의료 인프라 개선, 의료관광 증가 등이 있습니다.
아시아태평양의 감염성 질환 치료제 시장 개요
아시아태평양의 감염병 치료제 시장은 중국, 인도, 일본, 한국, 호주 및 기타 아시아태평양으로 세분화됩니다. 아시아태평양은 예측 기간 동안 가장 빠른 CAGR을 나타낼 것으로 예상됩니다. 이 지역 시장은 세계 헬스케어 지출 증가, 만성 질환 및 감염성 질환의 유병률 증가, 노인 인구 증가로 인해 성장할 것으로 예상됩니다. 중국에서는 인플루엔자, B형 간염, 전염성 설사 등의 감염성 질환이, 인도에서는 장티푸스, 말라리아, 황달, 결핵, 에이즈 등이 흔한 질병으로 꼽힙니다. Frontiers Public Health에 따르면 인플루엔자, B형 간염, 전염성 설사병은 중국에서 흔히 볼 수 있는 세 가지 전염병으로, 인플루엔자의 겨울 성수기는 2021년 중국에서 코로나19가 발생한 시기와 겹칩니다. 2020년 세계은행 중국 담당 국장에 따르면 중국은 인구 증가, 야생동물, 서식지 분절화, 가축 생산량 증가 등으로 인해 감염 위험이 높다고 합니다. 세계은행 이사회는 중국의 전염병 발생률 증가를 고려하여 신흥 전염병 예방, 대비 및 대응 프로젝트에 3억 달러의 대출을 승인했습니다. 이를 통해 인수공통전염병 및 기타 신흥 건강 위협의 위험을 줄일 수 있습니다. 이처럼 전염병 발병률 증가와 이러한 질병을 통제하기 위해 취해진 조치로 인해 향후 몇 년동안 중국의 전염병 치료제 시장이 성장할 것으로 예상됩니다.
2030년까지 아시아태평양 감염성 질환 치료제 시장 매출 및 예측(금액)
아시아태평양의 감염성 질환 치료제 시장 세분화
아시아태평양의 감염성 질환 치료제 시장은 약물 유형별, 적응증별, 투여 경로별, 유통 채널별, 국가별로 세분화되어 있습니다.
약물 유형별로 아시아태평양의 감염 치료제 시장은 항바이러스제, 항균제, 항진균제, 기타로 나뉘며, 2022년 항바이러스제가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
적응증 측면에서 아시아태평양의 감염병 치료제 시장은 HIV, 간염, 결핵, 인플루엔자, HPV, 기타로 구분되며, 2022년에는 HIV가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
투여 경로에 따라 아시아태평양의 감염 치료제 시장은 경구제, 비경구제, 국소제, 기타로 구분되며, 2022년 경구제가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
유통 채널에 따라 아시아태평양의 감염병 치료제 시장은 병원 약국, 소매 약국, 기타로 구분됩니다. 병원 약국이 2022년 가장 큰 시장 점유율을 차지했습니다.
국가별로는 중국, 일본, 인도, 인도, 호주, 한국, 기타 아시아태평양으로 나뉘며, 2022년 아시아태평양 감염병 치료제 시장 점유율은 중국이 독차지했습니다.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck &Co Inc, Pfizer Inc, Shionogi &Co Ltd는 아시아태평양의 감염 치료제 시장에서 활동하는 주요 기업 중 일부입니다. 아시아태평양의 감염성 질환 치료제 시장에서 활동하는 주요 기업 중 일부입니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 아시아태평양 감염성 질환 치료제 시장 - 주요 시장 역학
- 아시아태평양 감염성 질환 치료제 시장 - 주요 시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후 동향
- 성장 촉진요인과 억제요인의 영향
제5장 감염성 질환 치료제 시장-아시아태평양 시장 분석
- 아시아태평양 감염성 질환 치료제 시장 매출, 2022년-2030년
제6장 아시아태평양 감염성 질환 치료제 시장 분석 : 약제 클래스별
- 항바이러스제
- 항세균제
- 항진균제
- 기타
제7장 아시아태평양 감염성 질환 치료제 시장 분석 : 적응증별
- HIV
- 간염
- 결핵
- 인플루엔자
- HPV
- 기타
제8장 아시아태평양 감염성 질환 치료제 시장 분석 : 투여 경로별
- 경구
- 비경구
- 국소
- 기타
제9장 아시아태평양 감염성 질환 치료제 시장 분석 : 유통 채널별
- 병원 약국
- 소매 약국
- 기타
제10장 아시아태평양 감염성 질환 치료제 시장 : 국가별 분석
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
제11장 감염성 질환 치료제 시장-업계 상황
- 감염성 질환 치료제 시장 성장 전략
- 무기적 성장 전략
- 유기적 성장 전략
제12장 기업 개요
- Pfizer Inc
- Gilead Sciences Inc
- F. Hoffmann-La Roche Ltd
- Shionogi & Co Ltd
- Bayer AG
- GSK Plc
- AbbVie Inc
- Merck & Co Inc
- Astellas Pharma Inc
제13장 부록
LSH 24.10.31The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.
Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market
The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.
Asia Pacific Infectious Disease Therapeutics Market Overview
The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.
Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Infectious Disease Therapeutics Market Segmentation
The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.
Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
- 4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
- 4.2 Market Drivers
- 4.2.1 Rising Prevalence of Infectious Disease
- 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
- 4.3 Market Restraints
- 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
- 4.4 Market Opportunities
- 4.4.1 Growing Opportunities in Developing Nations
- 4.4.2 Escalating Threat of Antibiotic Resistance
- 4.5 Future Trends
- 4.5.1 Rising Number of Product Approvals and Launches
- 4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis
- 5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class
- 6.1 Overview
- 6.2 Anti-Viral
- 6.2.1 Overview
- 6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3 Anti-bacterial
- 6.3.1 Overview
- 6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Anti-fungal
- 6.4.1 Overview
- 6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 6.5 Others
- 6.5.1 Overview
- 6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication
- 7.1 Overview
- 7.2 HIV
- 7.2.1 Overview
- 7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3 Hepatitis
- 7.3.1 Overview
- 7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Tuberculosis
- 7.4.1 Overview
- 7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Influenza
- 7.5.1 Overview
- 7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6 HPV
- 7.6.1 Overview
- 7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration
- 8.1 Overview
- 8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3 Parenteral
- 8.3.1 Overview
- 8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Topical
- 8.4.1 Overview
- 8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel
- 9.1 Overview
- 9.2 Hospital Pharmacies
- 9.2.1 Overview
- 9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4 Others
- 9.4.1 Overview
- 9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis
- 10.1 Asia Pacific Infectious Disease Therapeutics Market Overview
- 10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
- 10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
- 10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.2.1 Overview
- 10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.4.1 Overview
- 10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.6.1 Overview
- 10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
- 10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.8.1 Overview
- 10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
- 10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.10.1 Overview
- 10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.12.1 Overview
- 10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
11. Infectious Disease Therapeutics Market-Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
- 11.3 Inorganic Growth Strategies
- 11.3.1 Overview
- 11.4 Organic Growth Strategies
- 11.4.1 Overview
12. Company Profiles
- 12.1 Pfizer Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Gilead Sciences Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 F. Hoffmann-La Roche Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Shionogi & Co Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Bayer AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 GSK Plc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 AbbVie Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Merck & Co Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
13. Appendix
- 13.1 About The Insight Partners
